Dybly AG

Swiss Biotech Association

Not a member

Dybly develops pharmaceutical products for patients affected by inflammatory and fibrotic diseases. Our scientific results demonstrate activity in the following pathways: BET-Bromodomain (inhibition); Apo A1 (upregulation); Inflammation (downregulation); Fibrosis (downregulation); Blood cancers: MML and AML (suppression of proliferation).

http://www.dybly.com

Location

Bäumleingasse 18, 4051 Basel

Get Directions

Facts & figures

Type of organization

Private company
Year of foundation

2007
Number of employees in Switzerland

1-9

Key business

Core competencies

Therapeutics/vaccines (human)

You may also be interested in

LATAM Pharma Innovative Ventures AG

LATAM Pharma offers made-to-measure solutions of immunization to public and private markets in Latin American and Caribbean countries.
6300 Zug

Member

Onward Therapeutics SA

We are a development stage oncology company, focusing on the identification of innovative technologies and the development of truly breakthrough medicines for the treatment of cancer.
1066 Épalinges

Member

NovaGo Therapeutics

NovaGo is focused on human antibody therapeutics targeting blood vessel & nerve growth. Our proprietary antibodies target Nogo-A, one of the most potent vascular & nerve growth inhibitors & have the potential to be a safe & effective treatment in ophthalmology and central nervous system indications.
8952 Schlieren

Member